arrow
L

Laura Bergamaschi

Cambridge University Hospitals NHS Foundation Trust
H指数:23
被引数:6,072

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Disease-specific B cell clones are shared between patients with Crohn's disease

克罗恩病患者的疾病特异性B细胞克隆存在共享现象。

2025-04-170
OA
Spatial distribution of tumour immune in fi ltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy
2024-08-011
OAAI
Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case
2024-01-042
OAAI
Targeting NF-κB signaling in B cells as a potential new treatment modality for ANCA-associated vasculitis

靶向b细胞中的nf-κb信号传导作为ANCA相关血管炎的潜在新治疗方式

2024-01-013
OA
Article Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity
2023-06-0110
OAAI
Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups
2023-03-2711
OAAI
A patient-centric modeling framework captures recovery from SARS-CoV-2 infection
2023-01-3024
OAAI
The impact of hypoxia on B cells in COVID-19
2022-03-0119
OAAI
B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination
2022-02-0131
OAAI
Dynamic regulation of hypoxia-inducible factor-1 α activity is essential for normal B cell development (vol 21, pg 1408, 2020)
2021-09-140
OA
Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease
IMMUNITY
IF26.3
2021-06-01219
OAAI
Single-cell multi-omics analysis of the immune response in COVID-19

新型冠状病毒肺炎免疫应答的单细胞多组学分析

2021-04-20389
OAAI
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

在没有体液免疫的情况下用remdesivir治疗新型冠状病毒肺炎: 一例病例报告

2020-12-1492
OAAI
Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant
2020-09-0146
OAAI